Winston Medical Supply Co (6817) Fair Value & Analysis
Healthcare · TW · Market cap 1.2B TWD
Fair value as of: Jun 25, 2026
Analysis
Winston Medical Supply Co (6817) currently trades at 60.00 TWD, while our model-based Fair Value estimate is 126.25 TWD — implying the stock looks roughly 110.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Winston Medical Supply Co.,Ltd. develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products in Taiwan and internationally. The company offers sterile ophthalmic preparations comprising gels, suspensions, solutions, and emulsions; hormone preparations, which primarily cover birth control and oral suspension for cancer related cachexia; external use preparations comprising ointments; and other oral preparations that are in oral dosage forms, such as powders, troches, tablets, film coated tablets, chewables, and capsules for the treatment of colds, gastrointestinal issues, and other indications. It also offers medical equipment, medical beauty products, and health food. In addition, the company engages in import and export trade; and manufacturers' agency and bidding business activities. The company was founded in 1974 and is based in Tainan City, Taiwan. Winston Medical Supply Co., Ltd. is a subsidiary of Medigen Biotechnology Corp.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Winston Medical Supply Co (6817) undervalued?
What is the fair value of 6817?
What is the quality score of 6817?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.